Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

FDA Advisory Committee recommends non-approval of liprotamase for exocrine pancreatic insufficiency

Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted today to recommend non-approval of liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT), currently under FDA review for the treatment of exocrine pancreatic insufficiency (EPI).

13 Jan 2011

FDA panel rejects new pancreatic enzyme replacement drug

Eli Lilly & Co did not win the support of the U.S. advisory panel on Wednesday for its one-of-its kind drug not made from pig enzymes to help certain pancreatic patients digest food. A Food and Drug Administration panel of outside experts in a 7-4 vote said they were not convinced the experimental medicine, known chemically as liprotamase, worked well enough for patients to absorb enough needed nutrients. One member of the panel abstained.

12 Jan 2011

Neurology professor receives MFRF's 'See the Light' award for Tay-Sachs research

Miguel Sena-Esteves, PhD, associate professor of neurology at the University of Massachusetts Medical School, was presented with the annual "See the Light" award from the Mathew Forbes Romer Foundation in recognition of his work for leading the fight against children's genetic diseases of the brain.

12 Jan 2011

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK

Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).

11 Jan 2011

Study to identify early warning biomarkers for presence of breast and prostate cancers

Using biological samples taken from patients and state-of-the-art biochemical techniques, a Florida State University researcher is working to identify a variety of "biomarkers" that might provide earlier warnings of the presence of breast and prostate cancers.

11 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

Predator microbes may work against antibiotic resistant disease-causing bacteria: Study

There are predators in the bacterial world that consume other bacteria, much as predators attack prey in the animal world. A team led by researchers at the University of Medicine and Dentistry of New Jersey-New Jersey Dental School suggests that some of these predator microbes might be put to work against disease-causing bacteria that have become resistant to antibiotics.

11 Jan 2011

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.

7 Jan 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

7 Jan 2011

DARA regains compliance for continued listing on The NASDAQ Capital Market

DARA BioSciences, Inc. today announced that, on January 5, 2011, NASDAQ notified the Company that it has regained compliance with the minimum stockholders' equity requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5550(b)(1).

7 Jan 2011

Targeted Genetics acquires Biocontrol

Targeted Genetics Corporation, today announced the completion of the acquisition of Biocontrol Limited.

7 Jan 2011

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world's largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization of a galectin-3 test for Siemens' automated immunoassay platforms for clinical laboratories.

7 Jan 2011

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Amira Pharmaceuticals, Inc. announced today the publication of its findings in the Journal of Pharmacology and Experimental Therapeutics which describes the biologic effects and the characterization of AM095, a lysophosphatidic acid receptor 1 antagonist, in various in vitro and in vivo models of fibrotic disease.

6 Jan 2011

Scientists identify prognostic biomarker to treat patients with HCV

Scientists at Inserm and Institut Pasteur have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work, published in The Journal of Clinical Investigation, demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin.

6 Jan 2011

Bacteria adopt defence strategy to promote antibiotic resistance

Genetic resistance to antibiotics is not the only trick bacteria use to resist eradication- they also have a second defence strategy known as persistence that can kick in.

6 Jan 2011

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.

6 Jan 2011

DARA BioSciences closes registered public offering

On December 28, 2010, DARA BioSciences, Inc. announced that it planned to raise up to $4 million through a registered public offering of units comprised of shares of Series A convertible preferred stock and warrants to purchase shares of common stock. Due to strong demand for the offered securities, the Company increased the size of the offering to up to $4.8 million.

5 Jan 2011

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

A new study shows that vitamin D deficiency could be linked to the development and severity of certain autoimmune lung diseases.

4 Jan 2011

Peptide in blood and tissue inhibits growth of breast tumors

Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.

4 Jan 2011

Fibrosis News and Research

Further Reading

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FDA Advisory Committee recommends non-approval of liprotamase for exocrine pancreatic insufficiency

FDA panel rejects new pancreatic enzyme replacement drug

Neurology professor receives MFRF's 'See the Light' award for Tay-Sachs research

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK

Study to identify early warning biomarkers for presence of breast and prostate cancers

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Predator microbes may work against antibiotic resistant disease-causing bacteria: Study

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

DARA regains compliance for continued listing on The NASDAQ Capital Market

Targeted Genetics acquires Biocontrol

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Scientists identify prognostic biomarker to treat patients with HCV

Bacteria adopt defence strategy to promote antibiotic resistance

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences closes registered public offering

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

Peptide in blood and tissue inhibits growth of breast tumors

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News